Details
Stereochemistry | ACHIRAL |
Molecular Formula | C31H44N2O5S |
Molecular Weight | 556.7587 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCc1c(c2cc(ccc2o1)NS(=O)(=O)C)C(=O)c3ccc(cc3)OCCCN(CCCC)CCCC
InChI
InChIKey=ZQTNQVWKHCQYLQ-UHFFFAOYSA-N
InChI=1S/C31H44N2O5S/c1-5-8-12-29-30(27-23-25(32-39(4,35)36)15-18-28(27)38-29)31(34)24-13-16-26(17-14-24)37-22-11-21-33(19-9-6-2)20-10-7-3/h13-18,23,32H,5-12,19-22H2,1-4H3
DescriptionCurator's Comment:: description was created based on several sources, including:
https://www.drugs.com/ppa/dronedarone.html | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fa41601-7fb5-4155-8e50-2ae903f0d2d6 | http://www.rxlist.com/multaq-drug.htm
Curator's Comment:: description was created based on several sources, including:
https://www.drugs.com/ppa/dronedarone.html | https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7fa41601-7fb5-4155-8e50-2ae903f0d2d6 | http://www.rxlist.com/multaq-drug.htm
Dronedarone is an antiarrhythmic that is FDA approved for the treatment of atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF). Dronedarone is multichannel blocker. Common adverse reactions include abdominal pain, diarrhea, indigestion, nausea, vomiting, asthenia and raised serum creatinine. Dronedarone has potentially important pharmacodynamics interactions: Digoxin: Consider discontinuation or halve dose of digoxin before treatment and monitor; Calcium channel blockers (CCB): Initiate CCB with low dose and increase after ECG verification of tolerability; Beta-blockers: May provoke excessive bradycardia, Initiate with low dose and increase after ECG verification of tolerability.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1914276 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25182566 |
|||
Target ID: CHEMBL1250417 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21279331 |
1.0 µM [IC50] | ||
Target ID: CHEMBL340 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | MULTAQ Approved UseMULTAQ® is indicated to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF) [see Clinical Studies (14) Launch Date1.24640638E12 |
|||
Primary | MULTAQ Approved UseMULTAQ® is indicated to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF) [see Clinical Studies (14) Launch Date1.24640638E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
96.2 ng/mL |
1600 mg single, oral dose: 1600 mg route of administration: Oral experiment type: SINGLE co-administered: METOPROLOL |
DRONEDARONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1386 ng × h/mL |
1600 mg single, oral dose: 1600 mg route of administration: Oral experiment type: SINGLE co-administered: METOPROLOL |
DRONEDARONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
12 h |
1600 mg single, oral dose: 1600 mg route of administration: Oral experiment type: SINGLE co-administered: METOPROLOL |
DRONEDARONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy, 20-97 years n = 3282 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: 20-97 years Sex: M+F Population Size: 3282 Sources: |
Disc. AE: Gastrointestinal disorders, QT interval prolonged... AEs leading to discontinuation/dose reduction: Gastrointestinal disorders (3.2%) Sources: QT interval prolonged (1.5%) |
1600 mg 2 times / day multiple, oral Highest studied dose Dose: 1600 mg, 2 times / day Route: oral Route: multiple Dose: 1600 mg, 2 times / day Sources: |
healthy, 21-40 years Health Status: healthy Age Group: 21-40 years Sex: M Sources: |
|
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Disc. AE: Diarrhea, Nausea... AEs leading to discontinuation/dose reduction: Diarrhea (6.7%) Sources: Page: p. 103Nausea (3.9%) Abdominal pain upper (2%) Abdominal pain (1.9%) Vomiting (1.7%) Dyspepsia (1.3%) Nasopharyngitis (3.7%) Upper respiratory tract infection (2.9%) Dizziness (3.4%) Blood creatinine increased (2.5%) Hepatic enzyme increased (1.2%) Blood urea increased (0.4%) Bradycardia (2.6%) Palpitations (1.1%) Cardiac failure congestive (1.3%) Cardiac failure (0.8%) Fatigue (2.7%) Oedema peripheral (4.2%) Back pain (3.3%) Arthralgia (3.1%) Pain in extremity (2.1%) Cough (2.2%) Dyspnoea (2.3%) Vertigo (1.3%) |
400 mg 2 times / day steady, oral Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: NYHA Class IV heart failure | NYHA Class II - III heart failure Age Group: adult Sources: |
Other AEs: Heart failure... Other AEs: Heart failure (grade 5) Sources: |
600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 66 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 66 Sources: Page: p. 103 |
Disc. AE: Diarrhea, Vomiting... AEs leading to discontinuation/dose reduction: Diarrhea (7.6%) Sources: Page: p. 103Vomiting (1.5%) Dyspepsia (3%) Abdominal pain (1.5%) Nasopharyngitis (4.5%) Electrocardiogram QT prolonged (1.5%) Blood creatinine increased (1.5%) Hepatic enzyme increased (4.5%) Blood urea increased (3%) Bradycardia (1.5%) Palpitations (6.1%) Cardiac failure congestive (4.5%) Cardiac failure (4.5%) Fatigue (4.5%) Cough (1.5%) Hypokalemia (3%) Vertigo (4.5%) |
800 mg 2 times / day multiple, oral Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 62 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 62 Sources: Page: p. 103 |
Disc. AE: Diarrhea, Nausea... AEs leading to discontinuation/dose reduction: Diarrhea (29%) Sources: Page: p. 103Nausea (8.1%) Vomiting (3.2%) Abdominal pain (3.2%) Influenza (3.2%) Upper respiratory tract infection (1.6%) Dizziness (4.8%) Electrocardiogram QT prolonged (3.2%) Hepatic enzyme increased (1.6%) Blood urea increased (3.2%) Bradycardia (6.5%) Palpitations (4.8%) Cardiac failure congestive (1.6%) Cardiac failure (1.6%) Fatigue (3.2%) Atrial tachycardia (4.8%) Cough (4.8%) Vertigo (3.2%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
QT interval prolonged | 1.5% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy, 20-97 years n = 3282 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: 20-97 years Sex: M+F Population Size: 3282 Sources: |
Gastrointestinal disorders | 3.2% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy, 20-97 years n = 3282 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: 20-97 years Sex: M+F Population Size: 3282 Sources: |
Blood urea increased | 0.4% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Cardiac failure | 0.8% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Palpitations | 1.1% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Hepatic enzyme increased | 1.2% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Cardiac failure congestive | 1.3% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Dyspepsia | 1.3% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Vertigo | 1.3% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Vomiting | 1.7% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Abdominal pain | 1.9% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Abdominal pain upper | 2% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Pain in extremity | 2.1% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Cough | 2.2% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Dyspnoea | 2.3% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Blood creatinine increased | 2.5% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Bradycardia | 2.6% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Fatigue | 2.7% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Upper respiratory tract infection | 2.9% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Arthralgia | 3.1% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Back pain | 3.3% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Dizziness | 3.4% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Nasopharyngitis | 3.7% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Nausea | 3.9% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Oedema peripheral | 4.2% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Diarrhea | 6.7% Disc. AE |
400 mg 2 times / day steady, oral Recommended Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 989 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 989 Sources: Page: p. 103 |
Heart failure | grade 5 | 400 mg 2 times / day steady, oral Dose: 400 mg, 2 times / day Route: oral Route: steady Dose: 400 mg, 2 times / day Sources: |
unhealthy, adult Health Status: unhealthy Condition: NYHA Class IV heart failure | NYHA Class II - III heart failure Age Group: adult Sources: |
Abdominal pain | 1.5% Disc. AE |
600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 66 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 66 Sources: Page: p. 103 |
Blood creatinine increased | 1.5% Disc. AE |
600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 66 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 66 Sources: Page: p. 103 |
Bradycardia | 1.5% Disc. AE |
600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 66 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 66 Sources: Page: p. 103 |
Cough | 1.5% Disc. AE |
600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 66 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 66 Sources: Page: p. 103 |
Electrocardiogram QT prolonged | 1.5% Disc. AE |
600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 66 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 66 Sources: Page: p. 103 |
Vomiting | 1.5% Disc. AE |
600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 66 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 66 Sources: Page: p. 103 |
Blood urea increased | 3% Disc. AE |
600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 66 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 66 Sources: Page: p. 103 |
Dyspepsia | 3% Disc. AE |
600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 66 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 66 Sources: Page: p. 103 |
Hypokalemia | 3% Disc. AE |
600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 66 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 66 Sources: Page: p. 103 |
Cardiac failure congestive | 4.5% Disc. AE |
600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 66 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 66 Sources: Page: p. 103 |
Cardiac failure | 4.5% Disc. AE |
600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 66 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 66 Sources: Page: p. 103 |
Fatigue | 4.5% Disc. AE |
600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 66 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 66 Sources: Page: p. 103 |
Hepatic enzyme increased | 4.5% Disc. AE |
600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 66 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 66 Sources: Page: p. 103 |
Nasopharyngitis | 4.5% Disc. AE |
600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 66 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 66 Sources: Page: p. 103 |
Vertigo | 4.5% Disc. AE |
600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 66 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 66 Sources: Page: p. 103 |
Palpitations | 6.1% Disc. AE |
600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 66 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 66 Sources: Page: p. 103 |
Diarrhea | 7.6% Disc. AE |
600 mg 2 times / day multiple, oral Dose: 600 mg, 2 times / day Route: oral Route: multiple Dose: 600 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 66 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 66 Sources: Page: p. 103 |
Cardiac failure congestive | 1.6% Disc. AE |
800 mg 2 times / day multiple, oral Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 62 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 62 Sources: Page: p. 103 |
Cardiac failure | 1.6% Disc. AE |
800 mg 2 times / day multiple, oral Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 62 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 62 Sources: Page: p. 103 |
Hepatic enzyme increased | 1.6% Disc. AE |
800 mg 2 times / day multiple, oral Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 62 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 62 Sources: Page: p. 103 |
Upper respiratory tract infection | 1.6% Disc. AE |
800 mg 2 times / day multiple, oral Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 62 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 62 Sources: Page: p. 103 |
Diarrhea | 29% Disc. AE |
800 mg 2 times / day multiple, oral Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 62 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 62 Sources: Page: p. 103 |
Abdominal pain | 3.2% Disc. AE |
800 mg 2 times / day multiple, oral Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 62 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 62 Sources: Page: p. 103 |
Blood urea increased | 3.2% Disc. AE |
800 mg 2 times / day multiple, oral Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 62 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 62 Sources: Page: p. 103 |
Electrocardiogram QT prolonged | 3.2% Disc. AE |
800 mg 2 times / day multiple, oral Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 62 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 62 Sources: Page: p. 103 |
Fatigue | 3.2% Disc. AE |
800 mg 2 times / day multiple, oral Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 62 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 62 Sources: Page: p. 103 |
Influenza | 3.2% Disc. AE |
800 mg 2 times / day multiple, oral Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 62 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 62 Sources: Page: p. 103 |
Vertigo | 3.2% Disc. AE |
800 mg 2 times / day multiple, oral Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 62 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 62 Sources: Page: p. 103 |
Vomiting | 3.2% Disc. AE |
800 mg 2 times / day multiple, oral Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 62 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 62 Sources: Page: p. 103 |
Atrial tachycardia | 4.8% Disc. AE |
800 mg 2 times / day multiple, oral Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 62 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 62 Sources: Page: p. 103 |
Cough | 4.8% Disc. AE |
800 mg 2 times / day multiple, oral Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 62 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 62 Sources: Page: p. 103 |
Dizziness | 4.8% Disc. AE |
800 mg 2 times / day multiple, oral Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 62 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 62 Sources: Page: p. 103 |
Palpitations | 4.8% Disc. AE |
800 mg 2 times / day multiple, oral Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 62 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 62 Sources: Page: p. 103 |
Bradycardia | 6.5% Disc. AE |
800 mg 2 times / day multiple, oral Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 62 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 62 Sources: Page: p. 103 |
Nausea | 8.1% Disc. AE |
800 mg 2 times / day multiple, oral Dose: 800 mg, 2 times / day Route: oral Route: multiple Dose: 800 mg, 2 times / day Sources: Page: p. 103 |
unhealthy, adult n = 62 Health Status: unhealthy Condition: atrial fibrillation | atrial flutter Age Group: adult Sex: M+F Population Size: 62 Sources: Page: p. 103 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76,89 |
major | yes (co-administration study) Comment: administration of ketoconazole resulted in a 17- to 25- fold increase in dronedarone exposure; administration with rifampicin decreased dronedarone exposure by 80% Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76,89 |
||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76.0 |
no | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_ClinPharm_P1.pdf#page=76 Page: 76.0 |
unlikely |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2009/022425s000_Pharm_P1.pdf#page=59 Page: 59.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Mechanisms of action of antiarrhythmic drugs relative to the origin and perpetuation of cardiac arrhythmias. | 2001 Jan |
|
Electrophysiological effects of dronedarone (SR 33589), a noniodinated amiodarone derivative in the canine heart: comparison with amiodarone. | 2001 Jul |
|
Newer antiarrhythmic drugs. | 2001 May-Jun |
|
Chronic amiodarone evokes no torsade de pointes arrhythmias despite QT lengthening in an animal model of acquired long-QT syndrome. | 2001 Nov 27 |
|
Five novel single nucleotide polymorphisms in the CYP2C8 gene, one of which induces a frame-shift. | 2002 |
|
Recent advances in arrhythmia therapy: treatment and prevention of atrial fibrillation. | 2002 Apr |
|
New antiarrhythmic drugs for the treatment of atrial fibrillation. | 2002 Feb |
|
The JT-area indicates dispersion of repolarization in dogs with atrioventricular block. | 2002 Jun |
|
Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone. | 2002 May |
|
Effects of dronedarone and amiodarone on plasma thyroid hormones and on the basal and postischemic performance of the isolated rat heart. | 2002 May 31 |
|
Dronedarone for prevention of atrial fibrillation: a dose-ranging study. | 2003 Aug |
|
Effects of amiodarone and dronedarone on voltage-dependent sodium current in human cardiomyocytes. | 2003 Aug |
|
Electrophysiologic characterization of dronedarone in guinea pig ventricular cells. | 2003 Feb |
|
Dronerarone acts as a selective inhibitor of 3,5,3'-triiodothyronine binding to thyroid hormone receptor-alpha1: in vitro and in vivo evidence. | 2003 Feb |
|
Chronic amiodarone-induced inhibition of the Na+-K+ pump in rabbit cardiac myocytes is thyroid-dependent: comparison with dronedarone. | 2003 Jan |
|
Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels. | 2003 Nov |
|
IKr channel blockers: novel antiarrhythmic agents. | 2003 Oct |
|
Trials of new antiarrhythmic drugs for maintenance of sinus rhythm in patients with atrial fibrillation. | 2004 |
|
Effects of metabolites and analogs of amiodarone on alveolar macrophages: structure-activity relationship. | 2004 Aug |
|
Involvement of nitric oxide in amiodarone- and dronedarone-induced coronary vasodilation in guinea pig heart. | 2004 Aug 2 |
|
High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656. | 2004 Dec 17 |
|
A benefit-risk assessment of class III antiarrhythmic agents. | 2004 Nov |
|
The novel antiarrhythmic drug dronedarone: comparison with amiodarone. | 2005 Fall |
|
Pharmacological treatment of atrial fibrillation: mechanisms of action and efficacy of class III drugs. | 2006 |
|
[Dronedarone--a new therapeutic option for controlling atrial rhythm and ventricular frequency]. | 2006 Aug 25 |
|
Drug evaluation: dronedarone, a novel non-iodinated anti-arrhythmic agent. | 2006 Sep |
|
Topics on the Na+/Ca2+ exchanger: pharmacological characterization of Na+/Ca2+ exchanger inhibitors. | 2006 Sep |
|
Medical management of atrial fibrillation: state of the art. | 2006 Sep |
|
Dronedarone: an emerging agent with rhythm- and rate-controlling effects. | 2006 Sep |
|
Dronedarone: an amiodarone analog for the treatment of atrial fibrillation and atrial flutter. | 2007 Apr |
|
Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. | 2007 Aug 1 |
|
Effect of dronedarone on renal function in healthy subjects. | 2007 Dec |
|
Dronedarone in atrial fibrillation. | 2007 Dec 6 |
|
New antiarrhythmic treatment of atrial fibrillation. | 2007 Jul |
|
Effect of amiodarone and dronedarone administration in rats on thyroid hormone-dependent gene expression in different cardiac components. | 2007 Jun |
|
Comparative antiarrhythmic efficacy of amiodarone and dronedarone during acute myocardial infarction in rats. | 2007 Jun 14 |
|
A review of the investigational antiarrhythmic agent dronedarone. | 2007 Mar |
|
New antiarrhythmic drugs for establishing sinus rhythm in atrial fibrillation: what are our therapies likely to be by 2010 and beyond? | 2007 Nov |
|
Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. | 2007 Oct 17 |
|
Maintaining sinus rhythm--making treatment better than the disease. | 2007 Sep 6 |
|
[Efficacy of dronedarone in cardiac failure due to severe left ventricular systolic dysfunction. Results of the ANDROMEDA]. | 2008 |
|
[Efficacy of dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. Results of the EURIDIS and ADONIS]. | 2008 |
|
Concurrent Chagas' disease and borderline disseminated cutaneous leishmaniasis: The role of amiodarone as an antitrypanosomatidae drug. | 2008 Jun |
|
Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches. | 2008 Jun |
|
Acute inhibitory effect of dronedarone, a noniodinated benzofuran analogue of amiodarone, on Na+/Ca2+ exchange current in guinea pig cardiac ventricular myocytes. | 2008 Jun |
|
Dronedarone: a new treatment for atrial fibrillation. | 2008 Nov |
|
Dronedarone for the control of ventricular rate in permanent atrial fibrillation: the Efficacy and safety of dRonedArone for the cOntrol of ventricular rate during atrial fibrillation (ERATO) study. | 2008 Sep |
|
New horizons in antiarrhythmic therapy: will novel agents overcome current deficits? | 2008 Sep 22 |
|
Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope? | 2009 Jan |
|
The role of thyroid hormone nuclear receptors in the heart: evidence from pharmacological approaches. | 2010 Mar |
Patents
Sample Use Guides
One tablet of 400 mg twice a day with morning and evening meals.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12548079
In isolated ventricular myocytes, dronedarone inhibited rapidly activating delayed-rectifier K+ current (I(Kr)) (median inhibitory concentration [IC50] = 3 uM voltage-independent); slowly activating delayed-rectifier K+ current (I(Ks)) (IC50 approximately/= 10 uM voltage-dependent and time-, frequency-, or use-independent); and inward rectifier potassium current (I(K1)) (IC50 >/= 30 uM).
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QC01BD07
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
||
|
LIVERTOX |
331
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
||
|
NDF-RT |
N0000175426
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
||
|
WHO-ATC |
C01BD07
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
||
|
NCI_THESAURUS |
C47793
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DRONEDARONE
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
PRIMARY | |||
|
DB04855
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
PRIMARY | |||
|
N0000185503
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
PRIMARY | P-Glycoprotein Inhibitors [MoA] | ||
|
233698
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
PRIMARY | RxNorm | ||
|
208898
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
PRIMARY | |||
|
C118667
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
PRIMARY | |||
|
141626-36-0
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
PRIMARY | |||
|
7928
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
PRIMARY | |||
|
M4768
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
PRIMARY | Merck Index | ||
|
N0000182137
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
PRIMARY | Cytochrome P450 2D6 Inhibitors [MoA] | ||
|
7465
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
PRIMARY | |||
|
141626-36-0
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
PRIMARY | |||
|
SUB06408MIG
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
PRIMARY | |||
|
CHEMBL184412
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
PRIMARY | |||
|
N0000190114
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
PRIMARY | Cytochrome P450 3A Inhibitors [MoA] | ||
|
C65485
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
PRIMARY | |||
|
7382
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
PRIMARY | |||
|
JQZ1L091Y2
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
PRIMARY | |||
|
4112
Created by
admin on Fri Jun 25 22:36:14 UTC 2021 , Edited by admin on Fri Jun 25 22:36:14 UTC 2021
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE LESS ACTIVE (PARENT)
SALT/SOLVATE (PARENT)